Specify a stock or a cryptocurrency in the search bar to get a summary
Pharmanutra S.p.A
PHNPharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company's products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. It distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. The company was founded in 2003 and is based in Pisa, Italy. Address: Via Campodavela 1, Pisa, PI, Italy, 56122
Analytics
WallStreet Target Price
72.41 EURP/E ratio
48.3036Dividend Yield
1.64 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PHN
Dividend Analytics PHN
Dividend growth over 5 years
142 %Continuous growth
5 yearsPayout Ratio 5 years average
40 %Dividend History PHN
Stock Valuation PHN
Financials PHN
Results | 2019 | Dynamics |